We combined flow cytometry, LEGENDplexTM immune profiling, and preoperative/postoperative serum cytokine analyses to determine checkpoint molecules (e.g., PD-1, TIM-3, LAG-3), immune cell profiles, as well as key markers on tumor cells (CD44, PD-L1, MHC class I/II). The gene discussed is HAVCR2; the disease is neoplasm.